This final conversation from SurfingMASH’s EASL Congress 2024 preview includes two final papers, one covering MASLD drug development, and a diverse set of answers to Roger Green’s closing question.
Jörn Schattenberg discusses a paper he will present on a completely new concept to treat MASLD, a Phase 2a trial of a transglutaminase inhibitor, a compound originally developed for Celiac disease. Aleksander Krag describes as “exciting” the idea that this concept came from Celiac disease.
Michelle Long discusses a late breaker abstract, which means it is embargoed and she cannot share many details. This is another “really good use” of a big data set, in this case data from an array of Novo Nordisk trials.
With all the abstracts presented, Roger Green observes that this is the first major Congress preview SurfingMASH has done where the discussion focusesd on anything other than drug development, in this case data development.
Roger asks for a “big picture” lessons each panelist will leave Milano with. Michelle notes that while she likes Roger’s copmment about focus, she views Big Data development as driving a new, broader phase of drug development. The group agrees.
Beyond that, closing comments from the panelists vary in scope and focus, but share themes that have emerged throughout the discussion.